EU schizophrenia guidance highlights unmet needs
This article was originally published in Scrip
The European Medicines Agency's new guidelines on developing schizophrenia treatments now include recommendations on R&D that targets the condition's traditionally overlooked negative and cognitive symptoms. The guidelines are encouraging because they highlight areas of unmet need, but developmental challenges mean they will not "translate into the launch of marketed products in the mid-term", said Charlotte Mackey, a lead analyst at Datamonitor.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.